Cherwell Offers Process Validation Advice and Solutions at PHSS 2014
Cherwell Laboratories, specialist suppliers of products for environmental monitoring and process validation, have confirmed their support for the Pharmaceutical & Healthcare Sciences Society (PHSS) Annual Conference 2014.
Taking place on the 11–12 September 2014 at University College London UCL, School of Pharmacy, the conference will focus on “Processing challenging Pharmaceutical, Biopharmaceutical and Therapy products to GMP: Managing compliance, control, monitoring and efficiency challenges”. Experts from Cherwell will be available to offer practical microbiological advice and solutions.
With over 40 years’ experience, Cherwell has a reputation for providing high-quality solutions to meet the environmental monitoring and process validation requirements of the pharmaceutical and healthcare industries. The product range, which includes Redipor prepared media, SAS microbial air samplers and biological indicators, has been developed in response to changes in regulatory and customer-specific requirements.
Andrew Barrow, Sales Manager commented: “At Cherwell, we understand the importance of keeping up-to-date with the constantly changing regulatory, product and processing environments.” He added, “Our attendance at events, such as the PHSS Annual Conference, helps us to maintain our own levels of knowledge and offer expert advice on products and applications”.
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.